Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy

• Published in: Journal of nanobiotechnology Vol. 20; no. 1; p. 206
• Main Authors: Liu, Cui, Yan, Xiangji, Zhang, Yujie, Yang, Mei, Ma, Yana, Zhang, Yuanyuan, Xu, Qiuran, Tu, Kangsheng, Zhang, Mingzhen
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29-04-2022; BioMed Central; BMC
• Subjects: Administration, Oral; Animal models; Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Anti-inflammatory drugs; Antioxidants; Antioxidants - therapeutic use; Biocompatibility; Care and treatment; Cell organelles; Colitis - chemically induced; Colitis - drug therapy; Colitis, Ulcerative - chemically induced; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - prevention & control; Colon; Curcuma - metabolism; Curcumin; Cytokines; Disease; Disease Models, Animal; Dosage and administration; Drug dosages; Exosomes - metabolism; Feces; Health aspects; IL-1β; Inactivation; Inflammation; Inflammation - drug therapy; Inflammatory bowel disease; Inflammatory bowel diseases; Interleukin 6; Lipids; Lipopolysaccharides; Mass spectrometry; Mass spectroscopy; Medical research; Methods; Mice; Mice, Transgenic; Morphology; Mucosa; Nanomedicine; Nanoparticles; Nanotherapeutics; NF-kappa B - metabolism; NF-κB pathway; NF-κB protein; Oral administration; Proteins; Remission (Medicine); Sucrose; Toxicity; Transgenic mice; Tumor necrosis factor-α; Turmeric; Turmeric-derived nanoparticles; Ulcerative colitis; Wound healing; Zeta potential; China; United States > US; Nanotherapeutics; Turmeric-derived nanoparticles; NF-κB pathway; Oral administration; Ulcerative colitis
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-022-01421-w

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by diffuse inflammation of the colonic mucosa and a relapsing and remitting course. The current therapeutics are only modestly effective and carry risks for unacceptable adverse events, and thus more effective approaches to treat UC is clinically needed.
For this purpose, turmeric-derived nanoparticles with a specific population (TDNPs 2) were characterized, and their targeting ability and therapeutic effects against colitis were investigated systematically. The hydrodynamic size of TDNPs 2 was around 178 nm, and the zeta potential was negative (- 21.7 mV). Mass spectrometry identified TDNPs 2 containing high levels of lipids and proteins. Notably, curcumin, the bioactive constituent of turmeric, was evidenced in TDNPs 2. In lipopolysaccharide (LPS)-induced acute inflammation, TDNPs 2 showed excellent anti-inflammatory and antioxidant properties. In mice colitis models, we demonstrated that orally administrated of TDNPs 2 could ameliorate mice colitis and accelerate colitis resolution via regulating the expression of the pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, and antioxidant gene, HO-1. Results obtained from transgenic mice with NF-κB-RE-Luc indicated that TDNPs 2-mediated inactivation of the NF-κB pathway might partially contribute to the protective effect of these particles against colitis.
Our results suggest that TDNPs 2 from edible turmeric represent a novel, natural colon-targeting therapeutics that may prevent colitis and promote wound repair in colitis while outperforming artificial nanoparticles in terms of low toxicity and ease of large-scale production.